ARCHIVES

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

This article is from The Cancer Letter archive.

Vol. 31 No. 35 | September 30, 2005

Download PDF Visit The Full Archive

Related Articles

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

May 25, 2001

Workshop Calls For Improved Surgical Oncology Training Programs

December 2, 1983

Guest Editorial: FDA Must Address Economic Incentives to Resolve Drug Shortages Permanently

February 24, 2012

NCAB Asks For Cost Reimbursement n Patients In Clinical Trials Until More Data Available

October 5, 1984

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Oxandrolone And Education Improves Weight Gain

February 28, 2003